PDF herunterladen
Semin Thromb Hemost 2004; 30(1): 119-125
DOI: 10.1055/s-2004-822976
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Eicosanoid Regulation of Angiogenesis in Tumors

Daotai Nie1 , Kenneth V. Honn2
  • 1Departments of Radiation Oncology and Pathology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan
  • 2Professor, Departments of Radiation Oncology and Pathology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
22. März 2004 (online)

    Lizenzen und Reprints

Tumor angiogenesis, the formation of new capillary blood vessels in tumors from pre-existing vasculature, is required for tumor growth and progression. Eicosanoids, the bioactive lipids derived from arachidonic acid, possess potent and diverse biological activities. In response to stimuli, arachidonic acid is mobilized from phospholipid pools and metabolized by cyclooxygenases (COX), lipoxygenases (LOX), and p450 epoxygenases (EOX) to form a variety of eicosanoids. The involvement of eicosanoids in tumor angiogenesis and progression is implicated by the observations that nonsteroidal anti-inflammation drugs (NSAIDs) reduce tumor growth and angiogenesis. Subsequently, it is found that the levels of COX-2 and/or 12-LOX are frequently increased in various cancers. Further studies using molecular and pharmacological approaches have found that COX-2 and 12-LOX, when overexpressed in carcinoma cells, enhance their angiogenic potential and stimulate tumor growth. In this article, we discuss how COX and LOX in cancer cells modulate tumor angiogenesis and present the possibility of using NSAIDs and LOX inhibitors as antiangiogenesis agents.

KEYWORDS

Angiogenesis - cancer - eicosanoids - arachidonic acid - nonsteroidal anti-inflammatory drugs

REFERENCES

  • 1 Folkman J. Incipient angiogenesis.  J Natl Cancer Inst. 2000;  92 94-95
    CrossrefPubMedGoogle Scholar
  • 2 Bouck N, Stellmach V, Hsu S C. How tumors become angiogenic.  Adv Cancer Res. 1996;  69 135-174
    PubMedGoogle Scholar
  • 3 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.  Cell. 1996;  86 353-364
    CrossrefPubMedGoogle Scholar
  • 4 Folkman J. Angiogenesis and angiogenesis inhibition: an overview.  EXS. 1997;  79 1-8
    PubMedGoogle Scholar
  • 5 Volpert O V, Dameron K M, Bouck N. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity.  Oncogene. 1997;  14 1495-1502
    CrossrefPubMedGoogle Scholar
  • 6 Dameron K M, Volpert O V, Tainsky M A et al.. Control of angiogenesis in fibroblasts by P53 regulation of thromobspondin-1.  Science. 1994;  265 1582-1584
    CrossrefPubMedGoogle Scholar
  • 7 Rak J, Mitsuhashi Y, Bayko L et al.. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction or inhibition of tumor angiogenesis.  Cancer Res. 1995;  55 4575-4580
    PubMedGoogle Scholar
  • 8 Maxwell P H, Wiesener M S, Chang G W et al.. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.  Nature. 1999;  399 271-275
    CrossrefPubMedGoogle Scholar
  • 9 Shweiki D, Itin A, Soffer D et al.. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.  Nature. 1992;  359 843-845
    CrossrefPubMedGoogle Scholar
  • 10 Shweiki D, Neeman M, Itin A et al.. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.  Proc Natl Acad Sci USA. 1995;  92 768-772
    PubMedGoogle Scholar
  • 11 Plate K H, Breier G, Weich H A et al.. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo.  Nature. 1992;  359 845-848
    CrossrefPubMedGoogle Scholar
  • 12 Forsythe J A, Jiang B H, Iyeer N V et al.. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.  Mol Cell Biol. 1996;  16 4604-4613
    PubMedGoogle Scholar
  • 13 Hartmann A, Kunz M, Kostlin S et al.. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma.  Cancer Res. 1999;  59 1578-1583
    PubMedGoogle Scholar
  • 14 Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens.  Biochem Biophys Res Commun. 1998;  251 287-290
    CrossrefPubMedGoogle Scholar
  • 15 Jain R K, Safabakhsh N, Sckell A et al.. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.  Proc Natl Acad Sci USA. 1998;  95 10820-10825
    CrossrefPubMedGoogle Scholar
  • 16 Ruohola J K, Valve E M, Karkkainen M J et al.. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells.  Mol Cell Endocrinol. 1999;  149 29-40
    CrossrefPubMedGoogle Scholar
  • 17 Funk C D. Prostaglandins and leukotrienes: advances in eicosanoid biology.  Science. 2001;  294 1871-1875
    CrossrefPubMedGoogle Scholar
  • 18 Chandrasekharan N V, Dai H, Roos K L et al.. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression.  Proc Natl Acad Sci USA. 2002;  99 13926-13931
    CrossrefPubMedGoogle Scholar
  • 19 Smith W L, DeWitt D L, Garavito R M. Cyclooxygenases: structural, cellular and molecular biology.  Annu Rev Biochem. 2000;  69 145-182
    Google Scholar
  • 20 Molina M A, Sitja-Arnau M, Lemoine M G et al.. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.  Cancer Res. 1999;  59 4356-4362
    PubMedGoogle Scholar
  • 21 Tucker O N, Dannenberg A J, Yang E K et al.. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.  Cancer Res. 1999;  59 987-990
    PubMedGoogle Scholar
  • 22 Achiwa H, Yatabe Y, Hida T et al.. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas.  Clin Cancer Res. 1999;  5 1001-1005
    PubMedGoogle Scholar
  • 23 Wolff H, Saukkonen K, Anttila S et al.. Expression of cyclooxygenase-2 in human lung carcinoma.  Cancer Res. 1998;  58 4997-5001
    PubMedGoogle Scholar
  • 24 Hida T, Yatabe Y, Achiwa H et al.. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.  Cancer Res. 1998;  58 3761-3764
    PubMedGoogle Scholar
  • 25 Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma.  J Surg Oncol. 1998;  69 168-172
    CrossrefPubMedGoogle Scholar
  • 26 Hwang D, Scollard D, Byrne J et al.. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.  J Natl Cancer Inst. 1998;  90 455-460
    CrossrefPubMedGoogle Scholar
  • 27 Kutchera W, Jones D A, Matsunami N et al.. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect.  Proc Natl Acad Sci USA. 1996;  93 4816-4820
    CrossrefPubMedGoogle Scholar
  • 28 DuBois R N, Radhika A, Reddy B S et al.. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.  Gastroenterology. 1996;  110 1259-1262
    PubMedGoogle Scholar
  • 29 Gustafson-Svard C, Lilja I, Hallbook O et al.. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.  Gut. 1996;  38 79-84
    PubMedGoogle Scholar
  • 30 Kargman S L, O'Neill G P, Vickers P J et al.. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.  Cancer Res. 1995;  55 2556-2559
    PubMedGoogle Scholar
  • 31 Gupta S, Srivastava M, Ahmad N et al.. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.  Cancer. 2000;  42 73-78
    PubMedGoogle Scholar
  • 32 Tremblay C, Dore M, Bochsler P N et al.. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma.  J Natl Cancer Inst. 1999;  91 1398-1403
    CrossrefPubMedGoogle Scholar
  • 33 Tjandrawinata R R, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells.  Br J Cancer. 1997;  75 1111-1118
    CrossrefPubMedGoogle Scholar
  • 34 Chan G, Boyle J O, Yang E K et al.. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.  Cancer Res. 1999;  59 991-994
    PubMedGoogle Scholar
  • 35 Zimmermann K C, Sarbia M, Weber A A et al.. Cyclooxygenase-2 expression in human esophageal carcinoma.  Cancer Res. 1999;  59 198-204
    PubMedGoogle Scholar
  • 36 Wilson K T, Fu S, Ramanujam K S et al.. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.  Cancer Res. 1998;  58 2929-2934
    PubMedGoogle Scholar
  • 37 Subbaramaiah K, Norton L, Gerald W et al.. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3.  J Biol Chem. 2002;  277 18649-18657
    CrossrefPubMedGoogle Scholar
  • 38 Tsujii M, Kawano S, DuBois R N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.  Proc Natl Acad Sci USA. 1997;  94 3336-3340
    CrossrefPubMedGoogle Scholar
  • 39 Liu X H, Yao S, Kirschenbaum A et al.. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.  Cancer Res. 1998;  58 4245-4249
    PubMedGoogle Scholar
  • 40 Liu X H, Kirschenbaum A, Yao S et al.. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.  Clin Exp Metastasis. 1999;  17 687-694
    CrossrefPubMedGoogle Scholar
  • 41 Liu X H, Kirschenbaum A, Yao S et al.. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.  J Urol. 2000;  164 820-825
    PubMedGoogle Scholar
  • 42 Williams C S, Tsujii M, Reese J et al.. Host cyclooxygenase-2 modulates carcinoma growth.  J Clin Invest. 2000;  105 1589-1594
    PubMedGoogle Scholar
  • 43 Tsujii M, Kawano S, Tsuji S et al.. Cyclooxygenase regulates angiogenesis induced by colon cancer cells.  Cell. 1998;  93 705-716
    CrossrefPubMedGoogle Scholar
  • 44 Sawaoka H, Tsuji S, Tsujii M et al.. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.  Lab Invest. 1999;  79 1469-1477
    PubMedGoogle Scholar
  • 45 Tamura M, Sebastian S, Gurates B et al.. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells.  J Clin Endocrinol Metab. 2002;  87 3504-3507
    CrossrefPubMedGoogle Scholar
  • 46 Hull M A, Thomson J L, Hawkey C J. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells.  Gut. 1999;  45 529-536
    PubMedGoogle Scholar
  • 47 Pourtau J, Mirshahi F, Li H et al.. Cyclooxygenase-2 activity is necessary for the angiogenic properties of oncostatin M.  FEBS Lett. 1999;  459 453-457
    CrossrefPubMedGoogle Scholar
  • 48 Jones M K, Wang H, Peskar B M et al.. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.  Nat Med. 1999;  5 1418-1423
    PubMedGoogle Scholar
  • 49 Yamada M, Kawai M, Kawai Y et al.. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat.  Curr Eye Res. 1999;  19 300-304
    CrossrefPubMedGoogle Scholar
  • 50 BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants.  Am J Ophthalmol. 1978;  86 455-461
    PubMedGoogle Scholar
  • 51 Ziche M, Jones J, Gullino P M. Role of prostaglandin E1 and copper in angiogenesis.  J Natl Cancer Inst. 1982;  69 475-482
    PubMedGoogle Scholar
  • 52 Form D M, Auerbach R. PGE2 and angiogenesis.  Proc Soc Exp Biol Med. 1983;  172 214-218
    CrossrefPubMedGoogle Scholar
  • 53 Liu X H, Kirschenbaum A, Lu M et al.. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line.  J Biol Chem. 2002;  277 50081-50086
    CrossrefPubMedGoogle Scholar
  • 54 Amano H, Hayashi I, Endo H et al.. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.  J Exp Med. 2003;  197 221-232
    CrossrefPubMedGoogle Scholar
  • 55 Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2.  J Biol Chem. 1999;  274 17042-17048
    CrossrefPubMedGoogle Scholar
  • 56 Xin X, Yang S, Kowalski J et al.. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.  J Biol Chem. 1999;  274 9116-9121
    CrossrefPubMedGoogle Scholar
  • 57 Nie D, Lamberti M, Zacharek A et al.. Thromboxane A2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis.  Biochem Biophys Res Commun. 2000;  267 245-251
    CrossrefPubMedGoogle Scholar
  • 58 Daniel T O, Liu H, Morrow J D et al.. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.  Cancer Res. 1999;  59 4574-4577
    PubMedGoogle Scholar
  • 59 Ashton A W, Yokota R, John G et al.. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2).  J Biol Chem. 1999;  274 35562-35570
    CrossrefPubMedGoogle Scholar
  • 60 Hennig R, Ding X Z, Tong W G et al.. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue.  Am J Pathol. 2002;  161 421-428
    PubMedGoogle Scholar
  • 61 Ghosh J, Myers C E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells.  Proc Natl Acad Sci USA. 1998;  95 13182-13187
    CrossrefPubMedGoogle Scholar
  • 62 Tong W G, Ding X Z, Witt R C et al.. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway.  Mol Cancer Ther. 2002;  1 929-935
    PubMedGoogle Scholar
  • 63 Brash A R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate.  J Biol Chem. 1999;  274 23679-23682
    CrossrefPubMedGoogle Scholar
  • 64 Brash A R, Boeglin W E, Chang M S. Discovery of a second 15S-lipoxygenase in humans.  Proc Natl Acad Sci USA. 1997;  94 6148-6152
    CrossrefPubMedGoogle Scholar
  • 65 Shappell S B, Gupta R A, Manning S et al.. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.  Cancer Res. 2001;  61 497-503
    PubMedGoogle Scholar
  • 66 Jack G S, Brash A R, Olson S J et al.. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.  Hum Pathol. 2000;  31 1146-1154
    CrossrefPubMedGoogle Scholar
  • 67 Shappell S B, Boeglin W E, Olson S J et al.. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma.  Am J Pathol. 1999;  155 235-245
    PubMedGoogle Scholar
  • 68 Gao X, Grignon D J, Chbihi T et al.. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer.  Urology. 1995;  46 227-237
    CrossrefPubMedGoogle Scholar
  • 69 Ding X Z, Iversen P, Cluck M W et al.. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells.  Biochem Biophys Res Commun. 1999;  261 218-223
    CrossrefPubMedGoogle Scholar
  • 70 Natarajan R, Esworthy R, Bai W et al.. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor.  J Clin Endocrinol Metab. 1997;  82 1790-1798
    PubMedGoogle Scholar
  • 71 Natarajan R, Nadler J. Role of lipoxygenases in breast cancer.  Front Biosci. 1998;  3 E81-E88
    PubMedGoogle Scholar
  • 72 Connolly J M, Rose D P. Enhanced angiogenesis and growth of 12-lipoxygenase gene-transfected MCF-7 human breast cancer cells in athymic nude mice.  Cancer Lett. 1998;  132 107-112
    CrossrefPubMedGoogle Scholar
  • 73 Chen Y Q, Duniec Z M, Liu B et al.. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis.  Cancer Res. 1994;  54 1574-1579
    PubMedGoogle Scholar
  • 74 Hong S H, Avis I, Vos M D et al.. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.  Cancer Res. 1999;  59 2223-2228
    PubMedGoogle Scholar
  • 75 Hagmann W, Gao X, Zacharek A et al.. 12-Lipoxygenase in Lewis lung carcinoma cells: molecular identity, intracellular distribution of activity and protein, and Ca(2+)-dependent translocation from cytosol to membranes.  Prostaglandins. 1995;  49 49-62
    CrossrefPubMedGoogle Scholar
  • 76 Liu B, Marnett L J, Chaudhary A et al.. Biosynthesis of 12(S)-Hydroxyeicosatetraenoic acid by B16 amelanotic melanoma cells is a determinant of their metastatic potential.  Lab Invest. 1994;  70 314-323
    PubMedGoogle Scholar
  • 77 Chang W C, Liu Y W, Ning C C et al.. Induction of arachidonate 12-lipoxygenase mRNA by epidermal growth factor in A431 cells.  J Biol Chem. 1993;  268 18734-18739
    PubMedGoogle Scholar
  • 78 Chen B K, Kung H C, Tsai T Y et al.. Essential role of mitogen-activated protein kinase pathway and c-Jun induction in epidermal growth factor-induced gene expression of human 12-lipoxygenase.  Mol Pharmacol. 2000;  57 153-161
    PubMedGoogle Scholar
  • 79 Silletti S, Timar J, Honn K V et al.. Autocrine motility factor induces differential 12-lipoxygenase expression and activity in high- and low-metastatic K1735 melanoma cell variants.  Cancer Res. 1994;  54 5752-5756
    PubMedGoogle Scholar
  • 80 Chen B K, Chang W C. Overexpression of c-Fos enhances the transcription of human arachidonate 12-lipoxygenase in A431 cells.  Biochem Biophys Res Commun. 1999;  261 848-852
    CrossrefPubMedGoogle Scholar
  • 81 Nie D, Hillman G G, Geddes T et al.. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth.  Cancer Res. 1998;  58 4047-4051
    PubMedGoogle Scholar
  • 82 Tang D G, Grossi I M, Chen Y Q et al.. 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of αvβ3 integrins on endothelial cells.  Int J Cancer. 1993;  54 102-111
    PubMedGoogle Scholar
  • 83 Tang D G, Chen Y Q, Renaud C et al.. Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor.  J Cell Biol. 1993;  121 689-704
    CrossrefPubMedGoogle Scholar
  • 84 Tang D G, Diglio C A, Honn K V. Activation of microvascular endothelium by 12(S)-HETE leads to enhanced tumor cell adhesion via upregulation of surface expression of αvβ3 integrin: a post-transcriptional, PKC- and cytoskeleton-dependent process.  Cancer Res. 1994;  54 1119-1129
    PubMedGoogle Scholar
  • 85 Tang D G, Chen Y Q, Diglio C A et al.. Transcriptional activation of endothelial cell integrin αvβ3 protein kinase C activator 12(S)-HETE.  J Cell Sci. 1995;  108 2629-2644
    PubMedGoogle Scholar
  • 86 Brooks P C, Clark R AF, Cheresh D A. Requirement of vascular integrin αvβ3 for angiogenesis.  Science. 1994;  264 569-571
    CrossrefPubMedGoogle Scholar
  • 87 Honn K V, Grossi I M, Diglio C A et al.. Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE induced endothelial cell retraction.  FASEB J. 1989;  3 2285-2293
    PubMedGoogle Scholar
  • 88 Tang D G, Diglio C A, Honn K V. 12(S)-HETE-induced microvascular endothelial cell retraction results from PKC-dependent rearrangement of cytoskeletal elements and αvβ3 integrins.  Prostaglandins. 1993;  45 249-268
    CrossrefPubMedGoogle Scholar
  • 89 Honn K V, Tang D G, Grossi I et al.. Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction.  Cancer Res. 1994;  54 565-574
    PubMedGoogle Scholar
  • 90 Tang D G, Renaud C, Stojakovic S et al.. 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis.  Biochem Biophys Res Commun. 1995;  211 462-468
    CrossrefPubMedGoogle Scholar
  • 91 Setty B NJ, Graeber J E, Stuart M J. The mitogenic effect of 15- and 12-hydroxyeicosatetraenoic acid on endothelial cells may be mediated via diacylglycerol kinase inhibition.  J Biol Chem. 1987;  262 17613-17622
    PubMedGoogle Scholar

Kenneth HonnPh.D. 

Departments of Radiation Oncology and Pathology, Wayne State University School of Medicine and Karmanos Cancer Institute

431 Chemistry Bldg., Detroit, MI 48202

eMail: k.v.honn@wayne.edu

      >